Market research reports, consulting: Global Market Insights Inc.
We use cookies to enhance user experience. (Privacy Policy)

Aniridia Treatment Market Trends

Report ID: GMI9264
   |
Published Date: April 2024
 | 
Report Format: PDF

Download free sample

 Aniridia Treatment Market Trends

Advances in genetic testing and molecular diagnostics enable healthcare providers to tailor treatment strategies to the specific genetic mutations underlying aniridia caused by a faulty gene (PAX6) in individual patients. This personalized approach enhances treatment efficacy and patient outcomes, driving demand for targeted therapies and contributing to the expansion of the aniridia treatment market.
 

  • For instance, in 2020, Dr. Simpson's project at the University of British Columbia was granted research funding to support the development of a potential gene therapy for the inherited eye disease, aniridia. The study was focused on developing personalized treatment approaches leveraging genetic insights. Also, through advanced genetic testing and molecular analysis, the project aimed to tailor therapies to individual patients, optimizing treatment efficacy and outcomes.
     

Thus, growing constant support from government along with increasing awareness pertaining to rare disease especially in developed countries will spur the market growth.

Authors: Mariam Faizullabhoy, Gauri Wani
Frequently Asked Question(FAQ) :
Which prominent players are operating in the aniridia treatment market?
Key players operating in the aniridia treatment market are AbbVie Inc., Bausch & Lomb Incorporated, F. Hoffmann-La Roche Ltd, HumanOptics AG, Johnson & Johnson Vision, MORCHER GmbH, Novartis AG, Ophtec, Pfizer Inc., and REPER-NN LTD are among others.
How substantial is the aniridia treatment market in North America?
Why is the demand for congenital aniridia treatment rising?
What is the size of the aniridia treatment market?
Aniridia Treatment Market Scope

Report Content

Chapter 1   Methodology & Scope

1.1    Market scope & definitions

1.2    Research design

1.2.1    Research approach

1.2.2    Data collection methods

1.3    Base estimates & calculations

1.3.1    Base year calculation

1.3.2    Key trends for market estimation

1.4    Forecast model

1.5    Primary research and validation

1.5.1    Primary sources

1.5.2    Data mining sources

Chapter 2   Executive Summary

2.1    Industry 3600 synopsis

Chapter 3   Industry Insights

3.1    Industry ecosystem analysis

3.2    Industry impact forces

3.2.1    Growth drivers

3.2.1.1   Rising incidence rate of aniridia

3.2.1.2   Increasing awareness for rare diseases

3.2.1.3   Growing R&D investment

3.2.2    Industry pitfalls & challenges

3.2.2.1   Stringent regulatory requirements

3.3    Growth potential analysis

3.4    Pipeline analysis

3.5    Regulatory landscape

3.6    Porter's analysis

3.7    PESTEL analysis

Chapter 4   Competitive Landscape, 2023

4.1    Introduction

4.2    Company market share analysis

4.3    Company matrix analysis

4.4    Competitive analysis of major market players

4.5    Competitive positioning matrix

4.6    Strategy outlook matrix

Chapter 5   Market Estimates and Forecast, By Treatment Type, 2021 – 2032 ($ Mn)

5.1    Key trends

5.2    Medication

5.2.1    Type

5.2.1.1   Eye drop

5.2.1.2   Ointments

5.2.1.3   Other medication types

5.2.2    Distribution channel

5.2.2.1   Hospital pharmacies

5.2.2.2   Retail pharmacies

5.2.2.3   Online pharmacies

5.3    Surgery

5.3.1    Surgery type

5.3.1.1   Keratoplasty

5.3.1.2   Artificial iris implantation

5.3.1.3   Glaucoma drainage devices

5.3.1.4   Trabeculectomy

5.3.1.5   Goniotomy

5.3.1.6   Other surgery types

5.3.2    End-user

5.3.2.1   Hospitals

5.3.2.2   Specialty clinics

5.3.2.3   Ambulatory surgical centers

5.3.2.4   Other end-users

Chapter 6   Market Estimates and Forecast, By Type, 2021 – 2032 ($ Mn)

6.1    Key trends

6.2    Congenital aniridia

6.2.1    Isolated aniridia

6.2.2    WAGR syndrome

6.2.3    Gillespie syndrome

6.3    Acquired aniridia

Chapter 7   Market Estimates and Forecast, By Age Group, 2021 – 2032 ($ Mn)

7.1    Key trends

7.2    Pediatric

7.3    Adult

Chapter 8   Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)

8.1    Key trends

8.2    North America

8.2.1    U.S.

8.2.2    Canada

8.3    Europe

8.3.1    Germany

8.3.2    UK

8.3.3    France

8.3.4    Spain

8.3.5    Italy

8.3.6    Netherlands

8.3.7    Rest of Europe

8.4    Asia Pacific

8.4.1    Japan

8.4.2    China

8.4.3    India

8.4.4    Australia

8.4.5    South Korea

8.4.6    Rest of Asia Pacific

8.5    Latin America

8.5.1    Brazil

8.5.2    Mexico

8.5.3    Rest of Latin America

8.6    Middle East and Africa

8.6.1    Saudi Arabia

8.6.2    South Africa

8.6.3    UAE

8.6.4    Rest of Middle East and Africa

Chapter 9   Company Profiles

9.1    AbbVie Inc.

9.2    Bausch & Lomb Incorporated

9.3    F. Hoffmann-La Roche Ltd

9.4    HumanOptics AG

9.5    Johnson & Johnson Vision

9.6    MORCHER GmbH

9.7    Novartis AG

9.8    Ophtec

9.9    Pfizer Inc.

9.10    REPER-NN LTD.

   

Authors: Mariam Faizullabhoy, Gauri Wani
Buy Now
$4,123 $4,850
15% off
$4,280 $5,350
20% off
$5,845 $8,350
30% off
    Buy now
Premium Report Details

Base Year: 2023

Companies covered: 10

Tables & Figures: 295

Countries covered: 22

Pages: 150

Download Free Sample

Top